# SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program

**Authors:** Meiling Liu, Dekang Lv, Wenjing Yan, Yi Wu, Shulan Wang, Luoxuan Wang, Jie Lei, Deshun Zeng, Zifeng Wang, Fang Liu, Bing Deng, Quentin Liu, Bin He, Min Yan

PMC · DOI: 10.1186/s12967-025-06621-0 · Journal of Translational Medicine · 2025-05-30

## TL;DR

This study identifies how SLIT3 protein promotes differentiation in neuroblastoma tumors, mimicking spontaneous regression and offering new treatment possibilities.

## Contribution

The study reveals a novel mechanism by which SLIT3 induces neuroblastoma differentiation through intratumoral crosstalk and PLCβ/PKC signaling.

## Key findings

- SLIT3 induces neuroblastoma cell differentiation via intratumoral crosstalk and activates PLCβ/PKC signaling.
- Stage 4S-specific tumor cells show a spontaneous regression-like program with activated SLIT-ROBO signaling linked to better prognosis.
- SLIT3 suppresses tumor growth and promotes differentiation in both orthotopic and subcutaneous xenograft models.

## Abstract

Neuroblastoma, the most common pediatric extracranial solid tumor, has heterogeneous clinical outcomes ranging from malignant progression to spontaneous regression. With the highest frequency of the elusive spontaneous regression, low-risk INSS Stage 4S neuroblastoma represents an ideal model for mechanistic investigation. Spontaneous regression is often accompanied by tumor differentiation, but the mechanisms underlying this process remain largely unclear.

Single-nucleus transcriptomics (snRNA-seq) data of neuroblastoma samples were obtained from the Synapse repository to investigate the composition of heterogeneous tumor cell clusters. The feature of the Stage 4S-specific tumor cell subpopulation was revealed through differential expression analysis, pathway enrichment analysis and pseudotime analysis, followed by clinical significance validation on public cohort datasets. The biological function of secreted SLIT3 was validated using multiple in vitro models, including recombinant protein treatment, conditioned medium treatment, and cell lines coculture, to confirm the intratumoral crosstalk effect. Orthotopic and subcutaneous xenograft models were established to verify SLIT3's in vivo function. Cellular bulk RNA-seq analysis was performed with or without SLIT3 recombinant protein treatment to discover the downstream pathways activated by SLIT3, followed by validation with specific pathway inhibitors.

Analysis of snRNA-seq revealed a distinct subpopulation of tumor cells within INSS Stage 4S neuroblastoma, characterized by a spontaneous regression-like program progressing toward differentiation. Activated SLIT-ROBO signaling was found in the Stage 4S-specific tumor cell subpopulation, which strongly correlated with favorable prognosis. Further investigation into the secreted ligands in SLIT-ROBO related pathways revealed that SLIT3 displayed the most potent enrichment in Stage 4S tumors and the strongest differentiation-inducing effect. In vitro experiments using recombinant SLIT3 protein, conditioned medium, and cell lines coculture consistently demonstrated the capacity of SLIT3 to induce neuroblastoma cell differentiation via intratumoral crosstalk, as evidenced by increased neurite outgrowth and elevated expression of neuronal differentiation markers. Both orthotopic xenograft and subcutaneous xenograft models demonstrated that SLIT3 expression suppressed tumor growth, leading to in vivo tumor differentiation. Mechanistically, PLCβ/PKC signaling mediates the SLIT3-induced neuroblastoma cell differentiation.

Stage 4S-specific tumor cell subpopulation exhibits a spontaneous regression-like program, from which SLIT3 mediates intratumoral crosstalk and promotes neuroblastoma differentiation via PLCβ/PKC signaling. These findings provide new insights into the mechanism of spontaneous regression in neuroblastoma and offer novel therapeutic targets for differentiation-based treatment strategies.

The online version contains supplementary material available at 10.1186/s12967-025-06621-0.

## Linked entities

- **Genes:** SLIT3 (slit guidance ligand 3) [NCBI Gene 6586], robo3 (roundabout 3) [NCBI Gene 33314], plcB (phospholipase C) [NCBI Gene 880904], PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476]
- **Proteins:** SLIT3 (slit guidance ligand 3)
- **Diseases:** neuroblastoma (MONDO:0005072)

## Full-text entities

- **Genes:** HSPG2 (heparan sulfate proteoglycan 2) [NCBI Gene 3339] {aka HSPG, PLC, PRCAN, SJA, SJS, SJS1}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, SLIT3 (slit guidance ligand 3) [NCBI Gene 6586] {aka MEGF5, SLIL2, SLIT1, Slit-3, slit2}
- **Diseases:** Stage 4S (MESH:D006011), solid tumor (MESH:D009369), Neuroblastoma (MESH:D009447)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12123822/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12123822/full.md

---
Source: https://tomesphere.com/paper/PMC12123822